More than two years ago, when Allergan inked a $2.1 billion pact for Kythera, Bernstein analyst Ronny Gal wrote to clients that Allergan “obviously” has “much higher expectations than we do” for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results